/
Our hope is that, one day, tomorrow s epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms.
The business is unprofitable at the operating level (-4.60% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 53.2% YoY with margins expanding 21.1pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$283M
▲ +53.2% YoY
Net Income (TTM)
-$6M
▲ +72.9% YoY
Op. Margin
-2.95%
▲ +21.1pp YoY
ROIC
-2.85%
▲ +221.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$21M
▲ +148.7% YoY
Op. Cash Flow (TTM)
$23M
▲ +153.4% YoY
Net Debt
-$212M
Net Cash Position
Cash & Equiv.
$212M
Continue Research